



GIG
CYMRU
NHS
WALES

Ymddiriedolaeth GIG
Prifysgol Felindre
Velindre University
NHS Trust



Gwasanaeth Gwaed Cymru
Welsh Blood Service



Canolfan Ganser Felindre
Velindre Cancer Centre

Pencadlys Ymddiriedolaeth GIG Prifysgol Felindre
Velindre University NHS Trust Headquarters
2 Cwrt Charnwood
Heol Billingsley
Parc Nantgarw
Caerdydd/Cardiff
CF15 7QZ
Ffôn/Phone : (029) 20196161
<https://velindre.nhs.wales>

Date: 25th March 2024
Ref: CORP 2024 - 046

Dear xxxx

Freedom of Information request: Clinical Trials Landscape in Oncology (CORP 2024 – 046)

Thank you for your request for information which the Trust received on 26th February 2024.

A copy of your request, including the Trust's response, can be found below.

I trust this answers your request for information, however, should you not be satisfied with the information supplied or the process of supplying it, you have a right to complain and request a review. Please note that you must submit a request for a review within 40 days of the date of this letter.


You should forward your complaint to:

Mr Ian Bevan via FOI.VUNHST@wales.nhs.uk
Head of Information Governance
Velindre University NHS Trust
2, Charnwood Court
Heol Billingsley
Parc Nantgarw
Cardiff / Caerdydd
CF15 7QZ
Tel / Ffon - 029 20196161

Should you wish to take your complaint further, if you are still unhappy with the decision after review, you can contact the:

Information Commissioner's Office - Wales
2nd Floor,
Churchill House,
Churchill Way,
Cardiff,
CF10 2HH
Telephone: 0330 414 6421
email: wales@ico.org.uk

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.





GIG
CYMRU
NHS
WALES

Ymddiriedolaeth GIG
Prifysgol Felindre
Velindre University
NHS Trust



Gwasanaeth Gwaed Cymru
Welsh Blood Service




Canolfan Ganser Felindre
Velindre Cancer Centre

Pencadlys Ymddiriedolaeth GIG Prifysgol Felindre
Velindre University NHS Trust Headquarters
2 Cwrt Charnwood
Heol Billingsley
Parc Nantgarw
Caerdydd/Cardiff
CF15 7QZ
Ffôn/Phone : (029) 20196161
<https://velindre.nhs.wales>

Yours sincerely

Lauren Fear
Director of Corporate Governance and Chief of Staff
Velindre University NHS Trust
2 Charnwood Court
Heol Billingsley
Parc Nantgarw
Cardiff
CF15 7QZ

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.



1.a What tumour groups do you treat with systemic anti-cancer therapy at your centre?

	Tick all that apply
Head & Neck (H&N)	x
Central nervous system (CNS)	x
Skin/ Melanoma	x
Urology/ Renal	x
Gynae-Onc	x
Breast	x
Upper Gastrointestinal (UGI)	x
Lower Gastrointestinal (LGI)	x
Hepato-pancreatico-biliary (HPB)	x
Cancer of unknown primary (CUP) Lung	x
Sarcoma	x

1.b Since 2010, for what tumour groups has your organisation had clinical trials involving systemic anti-cancer therapy? Select all that apply.

	Tick all that apply
Head & Neck (H&N)	X
Central nervous system (CNS)	X
Skin/ Melanoma	X
Urology/ Renal	X
Gynae-Onc	X
Breast	X
Upper Gastrointestinal (UGI)	X
Lower Gastrointestinal (LGI)	X
Hepato-pancreatico-biliary (HPB)	X
Cancer of unknown primary (CUP) Lung	X
Sarcoma	x
None of the above (ensure you do not tick any other boxes)	

1.c In TOTAL, how many clinical trials (interventional Phase 0 - III) involving novel or novel combination or novel way of administering systemic anti-cancer therapies for solid cancers did you have in the Oncology department on 31 Dec in each year (provide a snapshot number) since 2010?

	Number of trials,
2010	19
2011	16
2012	24
2013	38
2014	46
2015	65
2016	68
2017	54
2018	50
2019	58
2020	57
2021	49
2022	42
2023	53

1.d Of the total number of clinical trials you reported in 1.1c, how many were solely funded by the NHS and NIHR (thus excluding trials funded by charity, government research councils like MRC, academic institutions and commercial companies)?

	Number of trials, n
2010	<6*
2011	<6*
2012	<6*
2013	<6*
2014	<6*
2015	<6*
2016	<6*
2017	<6*
2018	<6*
2019	9
2020	<6*
2021	<6*
2022	<6*
2023	7

* Where the figure provided is less than 6, and where simple calculations could identify fields that contain less than 6, the Trust has applied an exemption under Section 40(2) (personal data) of the Freedom of Information Act 2000. This is because the Trust believes there is a potential risk of individuals being able to be identified if the figures were disclosed.

1.e Of the total number of clinical trials you reported in 1.1c, how many were PHASE 1 trials?

	Number of trials, n
2010	0
2011	0
2012	0
2013	<6*
2014	<6*
2015	<6*
2016	<6*
2017	<6*
2018	<6*
2019	6
2020	<6*
2021	7
2022	6
2023	9

* Where the figure provided is less than 6, and where simple calculations could identify fields that contain less than 6, the Trust has applied an exemption under Section 40(2) (personal data) of the Freedom of Information Act 2000. This is because the Trust believes there is a potential risk of individuals being able to be identified if the figures were disclosed.

1.f Of the total number of clinical trials you reported in 1.Ic, how many were PHASE 2 trials?

	Number of trials, n
2010	0
2011	0
2012	0
2013	0
2014	<6*
2015	<6*
2016	<6*
2017	<6*
2018	<6*
2019	<6*
2020	<6*
2021	<6*
2022	7
2023	10

* Where the figure provided is less than 6, and where simple calculations could identify fields that contain less than 6, the Trust has applied an exemption under Section 40(2) (personal data) of the Freedom of Information Act 2000. This is because the Trust believes there is a potential risk of individuals being able to be identified if the figures were disclosed.

1.g Of the total number of clinical trials you reported in 1.Ic, how many were PHASE 3 trials?

	Number of trials, n
2010	0
2011	0
2012	0
2013	0
2014	<6*
2015	<6*
2016	<6*
2017	<6*
2018	<6*
2019	<6*
2020	<6*
2021	7
2022	6
2023	10

* Where the figure provided is less than 6, and where simple calculations could identify fields that contain less than 6, the Trust has applied an exemption under Section 40(2) (personal data) of the Freedom of Information Act 2000. This is because the Trust believes there is a potential risk of individuals being able to be identified if the figures were disclosed.

1.h On a separate note, how many Phase IV trials did you conduct in each year at your hospital/ Trust?

	Number of trials, n
2010	0
2011	0
2012	0
2013	0
2014	0
2015	0
2016	0
2017	0
2018	0
2019	<6*
2020	0
2021	0
2022	0
2023	0

* Where the figure provided is less than 6, and where simple calculations could identify fields that contain less than 6, the Trust has applied an exemption under Section 40(2) (personal data) of the Freedom of Information Act 2000. This is because the Trust believes there is a potential risk of individuals being able to be identified if the figures were disclosed.

1.i Of the total number of clinical trials you reported in 1.ic, how many involved another procedure such as surgery or radiotherapy in combination with the trailed systemic anti-cancer therapy within the trial?

	Number of trials, n
2010	<6*
2011	<6*
2012	<6*
2013	<6*
2014	<6*
2015	6
2016	10
2017	13
2018	11
2019	12
2020	8
2021	8
2022	9
2023	12

* Where the figure provided is less than 6, and where simple calculations could identify fields that contain less than 6, the Trust has applied an exemption under Section 40(2) (personal data) of the Freedom of Information Act 2000. This is because the Trust believes there is a potential risk of individuals being able to be identified if the figures were disclosed.

1.j Provide the total number of adult patients enrolled in phase I - III solid-cancer systemic anti-cancer therapy trials on 31 Dec of each year at your hospital/ Trust:

	Number of trials, n
2010	Data not available
2011	Data not available
2012	Data not available
2013	Data not available
2014	204
2015	177
2016	243
2017	291
2018	303
2019	253
2020	130
2021	161
2022	137
2023	111

1.k In each year, how many new Phase I - III clinical trials did you open for recruitment?

	Number of trials, n
2010	<6*
2011	<6*
2012	10
2013	19
2014	26
2015	39
2016	29
2017	27
2018	20
2019	22
2020	15
2021	26
2022	17
2023	23

* Where the figure provided is less than 6, and where simple calculations could identify fields that contain less than 6, the Trust has applied an exemption under Section 40(2) (personal data) of the Freedom of Information Act 2000. This is because the Trust believes there is a potential risk of individuals being able to be identified if the figures were disclosed.

2.I Post-BREXIT, what regulatory changes have had the greatest impact on the initiation of oncology trials at your centre?

No real impact following Brexit.

2.II Post-BREXIT, what regulatory changes have had the greatest impact on the conduct/ continuation of oncology trials at your centre?

No real impact following Brexit.

2.IIIa Post-BREXIT, have you observed any specific challenges related to regulatory compliance for initiating new oncology trials at your centre?

	Tick one
Yes	<input type="checkbox"/>
No	<input type="checkbox"/>
Unsure	<input type="checkbox"/>

2.IIIb If yes, please specify the regulatory challenges encountered:

This is subjective and therefore cannot be answered in the context of FOI.

2.IV a Have there been any notable changes in the regulatory reporting requirements for ongoing oncology trials post-BREXIT?

	Tick one
Yes	<input type="checkbox"/>
No	<input type="checkbox"/>
Unsure	<input type="checkbox"/>

2.IV b If yes, please elaborate on the changes and their impact on trial conduct:

This is subjective and therefore cannot be answered in the context of FOI.

2.V a Have there been any changes in the timeline for regulatory approvals post-BREXIT for initiating new oncology trials?

	Tick one
Yes	<input type="checkbox"/>
No	<input checked="" type="checkbox"/>
Unsure	<input type="checkbox"/>

2.V b If yes, please specify the nature of delays and their impact on trial initiation:

N/A

2.VI How has the communication and coordination with regulatory authorities changed post-BREXIT in the context of oncology trials?

Same as pre-Brexit

2.VIa Have there been any new documentation or compliance requirements introduced post-BREXIT for ongoing oncology trials?

	Tick one
Yes	
No	x
Unsure	

2.VIb If yes, please provide examples of the additional documentation or compliance measures introduced:

N/A

2.VII How has the training and education of clinical trial staff in your centre been impacted by regulatory changes post-BREXIT?

No impact

2.VIIIa Have there been any changes in the requirements for informed consent processes for oncology trials post-BREXIT?

	Tick one
Yes	
No	x
Unsure	

2.VIIIb If yes, please specify the nature of changes and their impact on the informed consent process:

N/A

2.IX How has the interpretation and implementation of Good Clinical Practice (GCP) guidelines evolved post-BREXIT in your centre?

GCP still applies and has not changed.
--

2.Xa Where staff updated or educated on regulatory changes post- BREXIT?

	Tick one
Yes	x
No	

2.Xb If yes, explain how:

Relevant staff within Velindre University NHS Trust were aware of measures being implemented by organisations such as Health and Care Research Wales and the MHRA, having the opportunity to feed into these discussions (citing the trials we had open/in set-up at the time). However, none of this contingency planning had a regulatory impact on our ability to open and run oncology clinical trials.

2.Xc If no, explain why not:

N/A

3.I In each year, how many Phase 0 - IV clinical trials did you have to discontinue due to a lack of funding? Comment on the funding sources affected:

	Number of trials, n
2010	0
2011	0
2012	0
2013	0
2014	0
2015	0
2016	0
2017	0
2018	0
2019	0
2020	0
2021	0
2022	0
2023	0

3.II Name all organisations, including your own, that sponsored and/or funded solid-cancer systemic-anticancer therapy trials at your centre in each year:

	Sponsors/ funders
2010	<ul style="list-style-type: none"> • Cardiff University • Liverpool University • University of Sheffield
2011	<ul style="list-style-type: none"> • AB Science • Roche • Royal Marsden NHS Foundation Trust • University College London • University of Cambridge • University of Oxford
2012	<ul style="list-style-type: none"> • Allos Therapeutics Inc. • Boehringer Ingelheim • Common Services Agency, NHS Scotland • Genentech Inc. & Hoffmann-La Roche Ltd

	<ul style="list-style-type: none"> • Millennium Pharmaceuticals Inc. • NCIC Clinical Trials Unit • NHS Greater Glasgow & Clyde and Glasgow University • Pfizer • Southampton University Hospitals NHS Trust • University College London • University Hospital Birmingham NHS Foundation Trust • University of Oxford • Velindre University NHS Trust
2013	<ul style="list-style-type: none"> • ACCORD (Academic and Clinical Central Office for Research & Development) • Astex Pharmaceuticals Inc. • AstraZeneca • BN Immunotherapies • Cardiff University • CRUK • Institute of Cancer Research ECMC • Joint UCLH/UCL Biomedical Research • Nektar Therapeutics • NHS Greater Glasgow & Clyde and Glasgow University • Novartis • Puma Biotechnology • Roche • The Institute of Cancer Research • University College London • University of Leeds • University of Liverpool • University of Sydney • University of Warwick • Verastem Inc
2014	<ul style="list-style-type: none"> • AGO study group • AstraZeneca • Bristol Myers Squibb • Cambridge University Hospitals NHS Foundation Trust • Cardiff University • Guy's & St Thomas' NHS Foundation Trust • Incyte Corporation • Medical Research Council • Medivation • NHS Greater Glasgow & Clyde and Glasgow University • Onyx Therapeutics Inc

	<ul style="list-style-type: none"> • Queen Mary University of London • Roche • Royal Marsden NHS Foundation Trust • Synta Pharmaceuticals Corp • Tesaro Inc • The Christie NHS Foundation Trust • The Institute of Cancer Research • University College London • University of Birmingham • University of Oxford • Velindre University NHS Trust
2015	<ul style="list-style-type: none"> • AB Science • All Ireland Cooperative Oncology Research Group • Astellas Pharma Europe Ltd • AstraZeneca • Bangor University • Boehringer Ingelheim • Brighton & Sussex Medical School • Bristol Myers Squibb • BTG PLC • Cardiff University • Clatterbridge Centre for Oncology NHS Trust • Eli Lilly • EORTC • ICR • Incyte Corporation • Institute of Cancer Research • Irish Clinical Oncology Research Group • Janssen Pharmaceuticals NV • Merck Sharp & Dohme LLC (Rahway, NJ) • NHS Greater Glasgow & Clyde and Glasgow University • Orion Corporation • PharmaMar • Roche • Royal Marsden NHS Foundation Trust • Sheffield Teaching Hospitals NHS Trust • Southampton University Hospitals NHS Trust • The All Ireland Cooperative Clinical Oncology Research Group

	<ul style="list-style-type: none"> • Unicancer • University College London • University Hospitals Bristol NHS Foundation Trust • University of Birmingham • University of Glasgow and NHS Greater Glasgow and Clyde • University of Leeds • University of Liverpool • University of Surrey • Velindre University NHS Trust
2016	<ul style="list-style-type: none"> • AbbVie Deutschland GmbH • Alliance Foundation Trials (AFT) • AstraZeneca • Belfast Health and Social Care Trust • Breast International Group • Cambridge University • Cardiff University • CRUK • GENMAB • MaNGO [Mario Negri Gynecologic Oncology Group] • MedImmune, LLC • Millennium Pharmaceuticals Inc. • Novartis • Pfizer • Roche • Royal Marsden NHS Foundation Trust • Sierra • Sierra • Southampton University Hospitals NHS Trust • Takeda (Previous sponsor: Millennium Pharmaceuticals Inc.) • The Institute for Cancer Research • tokai pharmaceuticals • UCL • University College London • University of Birmingham • University of Leicester • University of Oxford • University of Southampton • Velindre University NHS Trust • Xbiotech USA Inc

2017	<ul style="list-style-type: none"> • ARMO Biosciences • AstraZeneca • Bristol Myers Squibb • Cambridge University Hospitals NHS Foundation Trust • Cardiff University • CLOVIS • Daiichi Sankyo, Inc • Edinburgh University • Eisai Ltd • Genmab A/S • ICR • Incyte Corporation • Janssen • Merck Sharp & Dohme LLC (Rahway, NJ) • National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) • Newcastle upon Tyne Hospitals NHS Foundation Trust • NHS Greater Glasgow & Clyde and University of Glasgow • NOVARTIS • Novartis • Ono Pharmaceutical Co., Ltd • Oxford University • Roche • Sussex Health Outcomes Research & Education in Cancer • Takeda UK Limited • TC BIOPHARM • The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust • The University of Manchester • University College London • University of Birmingham • University of Leeds • University of Oxford • University of South Wales • University of Southampton • Velindre University NHS Trust
2018	<ul style="list-style-type: none"> • Abbvie • AstraZeneca • Bristol Myers Squibb • Cambridge University Hospitals NHS Foundation Trust • Cardiff University • Clovis Oncology Inc

	<ul style="list-style-type: none"> • EORTC • Gilead Sciences International Ltd • International Breast Cancer Study Group (IBCSG) • MRC CTU at UCL • NHS Greater Glasgow & Clyde and University of Glasgow • Polaris Group • Roche • Royal Marsden NHS Foundation Trust • Sheffield Teaching Hospitals NHS Foundation Trust • Swansea University • Synthon Biopharmaceuticals BV • The Clatterbridge Cancer Centre NHS Foundation Trust • The Institute of Cancer Research • The Walton Centre NHS Foundation Trust • University of Birmingham • University of Bristol • University of Edinburgh and NHS Lothian ACCORD • University of Oxford • Velindre University NHS Trust
2019	<ul style="list-style-type: none"> • Astellas Pharma Europe Ltd • AstraZeneca • Bangor University • Bayer AG • Bristol Myers Squibb • Cardiff Metropolitan University • Cardiff University • East & North Hertfordshire NHS Trust • Eisai Ltd • Exelixis Inc • Genmab A/S • Guy's & St Thomas' Foundation NHS Trust • Incyte Corporation • Johannes Gutenberg University Medical Center Mainz • Menarini Ricerche S.p.A. • Novartis Pharma AG • Regeneron Pharmaceuticals, Inc. • Roche • Sanofi • Stemline Therapeutics, Inc • SVMPharma Ltd

	<ul style="list-style-type: none"> • The Christie NHS Foundation Trust • The Institute of Cancer Research • The Newcastle upon Tyne Hospitals NHS Foundation Trust • The Royal Marsden NHS Foundation Trust • The Royal Surrey County Hospital • The University of Manchester • University College London • University College London Hospitals Nhs Foundation Trust • University of Birmingham • University of Nottingham • University of Oxford • University of South Wales • Velindre University NHS Trust
2020	<ul style="list-style-type: none"> • AstraZeneca • BeiGene, Ltd • Bristol Myers Squibb • Cardiff University • CRUK • Eli Lilly Cork Ltd • ERYTECH Pharma • Exelixis Inc • Fondazione IRCCS Istituto Nazionale Tumori, Milano • Greater Manchester Mental Health NHS Foundation Trust • Hywel Dda University Health Board • Imperial College London • Mario Negri Gynecology Oncology Group (MaNGO) • NHS Greater Glasgow and Clyde • Roche • Swansea University • The Institute of Cancer Research • Theradex Oncology • Ultimovacs AS • University College London • University of Oxford • Velindre University NHS Trust
2021	<ul style="list-style-type: none"> • AstraZeneca • Athenex • BioNTech RNA Pharmaceuticals GmbH • Bristol Myers Squibb

	<ul style="list-style-type: none"> • Cambridge University Hospitals NHS Foundation Trust • Cardiff University • DAIICHI SANKYO, INC • Eli Lilly and Company • F. Hoffmann-La Roche • G1 Therapeutics, Inc. • Genentech Inc • Genmab B.V. • GlaxoSmithKline • GlaxoSmithKline • i Therapeutics, Inc • King's College London • Merck Sharp & Dohme LLC (Rahway, NJ) • Merck Sharp & Dohme LLC (Rahway, NJ) • Merck Sharp & Dohme LLC (Rahway, NJ) • Millennium Pharmaceuticals, Inc • NHS Greater Glasgow and Clyde • North Bristol NHS Trust Research & Innovation • Orion Pharma • Pfizer • Public Health England • ROCHE • ROCHE • Scancell Ltd • Starpharma Pty Ltd • The Christie NHS Foundation Trust • The Institute of Cancer Research • The Royal Marsden NHS Foundation Trust • The University of Manchester • University College London (UCL) • University of Dundee • University of Leeds • University of Leeds • University of Oxford • Velindre University NHS Trust
2022	<ul style="list-style-type: none"> • Akamis Bio • Aneurin Bevan UHB • AstraZeneca • Boehringer Ingelheim • Cambridge University Hospitals NHS Foundation Trust • Cardiff University • F. Hoffmann-La Roche

	<ul style="list-style-type: none"> • IO Biotech ApS • Janssen • Merck Sharp & Dohme LLC (Rahway, NJ) • MRC • NHS Greater Glasgow & Clyde • Oxford Vacmedix UK Ltd. • Regeneron Pharmaceuticals • Sanofi • The Institute of Cancer Research • University College London • University Hospital Southampton NHS Foundation Trust • University of Birmingham • University of Leeds • University of South Wales
2023	<ul style="list-style-type: none"> • Amgen • AstraZeneca • AstraZeneca • BioNTech SE • Boehringer Ingelheim • Boston Scientific Corporation • Breast International Group • Bristol Myers Squibb • Cambridge University Hospitals NHS Foundation Trust • Cancer Research UK • Cardiff and Vale University Health Board • Cardiff University • Celcuity • DAIICHI SANKYO, INC • Eisai Ltd • Eli Lilly and Company • EORTC • Fondazione IRCCS Istituto Nazionale Tumori, Milano • Genentech Inc • Genmab A/S • Gustave Roussy • Guy's & St Thomas' Foundation NHS Trust • Imperial College London • IO Biotech ApS • King's College London • Merck Sharp & Dohme LLC (Rahway, NJ) • NHS Greater Glasgow & Clyde and University of Glasgow • Oxford Vacmedix UK Ltd. • Oxon Epidemiology • Pierre Fabre SA (PFSA) • Regeneron Pharmaceuticals • ROCHE • Royal Marsden NHS Foundation Trust • Sanofi • Scancell Ltd • Swansea University • The Christie NHS Foundation Trust • The Institute of Cancer Research • The University of Manchester • University College London • University Hospitals Bristol and Weston NHS Foundation Trust

	<ul style="list-style-type: none"> • University of Birmingham • University of Leeds • University of Leicester • University of Oxford • University of Southampton • University of Surrey • Velindre University NHS Trust
--	--

3.III How has the funding landscape for oncology pharmaceutical trials at your centre changed post-BREXIT?

	Tick one
Increased funding opportunities	
Decreased funding opportunities	
No significant change	x
Not Sure	

3.IV If there has been a change, please describe the main factors contributing to the

N/A

3.V How has the change in funding impacted the continuity of ongoing oncology

N/A

3.VI Are there specific types of trials more affected by funding challenges (e.g., Phase 1, investigator-initiated trials, certain types of systemic anti-cancer drugs, combination therapies, for certain tumour groups)?

N/A

3.VII How has the uncertainty surrounding BREXIT impacted the willingness of funding organisations to support oncology trials?

	Tick one
Significantly impacted	
Moderately impacted	
Minimally impacted	
No impact	
Not Sure	

This is subjective and therefore cannot be answered in the context of FOI.

3.VIII Answering on behalf of your organisation, are there any specific policy changes that would enhance funding opportunities for oncology trials post-BREXIT?

This is subjective and therefore cannot be answered in the context of FOI.

***3.IXa Have you explored alternative funding sources or strategies to mitigate potential funding challenges post-BREXIT?**

	Tick one
Yes	
No	x
Unsure	

3.IXb If yes, please share details of any successful strategies or approaches implemented:

N/A

3.X To what extent have patient advocacy groups played a role in supporting or influencing funding for oncology trials post-BREXIT in or for your organisation?

No impact

3.XIa Have there been any changes in the criteria or preferences of funding organisations when considering proposals for oncology trials post-BREXIT?

	Tick one
Yes	
No	x
Unsure	

3.XIb If yes, please elaborate on the key changes in criteria or preferences:

N/A

4.I Comment on collaborative challenges that affected or caused disruptions in the initiation or running of solid-cancer systemic anti- cancer therapy drugs:

	Collaborative Challenges
2010	N/A
2011	N/A
2012	N/A
2013	N/A
2014	N/A
2015	N/A
2016	N/A

2017	N/A
2018	N/A
2019	N/A
2020	N/A
2021	N/A
2022	N/A
2023	N/A

4.IIa Have there been challenges in maintaining international collaborations for oncology trials post-BREXIT?

	Tick one
Yes	
No	x
Unsure	

4.IIb If yes, please identify the main collaborative challenges faced:

N/A

4.IIIa Have changes in regulatory requirements impacted international partnerships in oncology trials?

	Tick one
Yes	
No	x
Unsure	

4.IIIb If yes, please elaborate on the specific regulatory aspects causing challenges:

N/A

4.IVa In your experience, have collaborative challenges affected the timeline and efficiency of oncology trials?

	Tick one
Yes	
No	
Unsure	

4.IVb If yes, please provide examples or instances where collaboration challenges led to

This is subjective and therefore cannot be answered in the context of FOI”

4.Va At your current NHS hospital, have there been challenges in aligning international ethical standards and practices for oncology trials post-BREXIT?

	Tick one
Yes	
No	x
Unsure	

4.Vb If yes, please elaborate on the specific ethical challenges faced and their impact on collaborative efforts:

N/A

4.VI How has the exchange of trial-related data and information with international partners been affected post-BREXIT?

No issues

4.VIIa In your organisation's experience, have there been any challenges related to differences in patient populations across international sites in oncology trials?

	Tick one
Yes	
No	x
Unsure	

4.VIIb If yes, please provide examples or instances where differences in patient

N/A

4.VIII How has the exchange of expertise and specialised resources with international collaborators been affected post-BREXIT?

Not affected.

4.IX From your organisation's perspective, what strategies or initiatives could enhance international collaboration in oncology trials in the post-BREXIT era?

This is subjective and therefore cannot be answered in the context of FOI.

5.Ia Have you become aware of or experienced any challenges related to the alignment of data privacy and protection regulations in international oncology trials post-BREXIT?

	Tick one
Yes	
No	x
Unsure	

5.1b If yes, please elaborate on the specific challenges faced and any measures

N/A

Thank you for taking the time to complete this survey.